| Popis: |
Neurolytic blocks have been used to relieve cancer pain for more than 50 years, and yet fair to good results have remained at the 50–60% range [1]. There exists a need to redefine the role of neurolytic blocks in patients with cancer pain, given the advent of intrathecal and epidural morphine [2] and given the fact that advances in cancer therapy have succeeded significantly in prolonging the life expectancy of patients with cancer [3]. Recent studies have increased awareness with regard to the prevalence and severity of cancer pain, thus behooving us to take a closer look at the efficacy of neurolytic blocks. |
